Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Hansa Biopharma

DB:24H
Snowflake Description

Excellent balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
24H
DB
SEK4B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Hansa Biopharma AB (publ), a biopharmaceutical company, focuses on developing novel immunomodulatory enzymes for organ transplantation and autoimmune diseases. The last earnings update was 60 days ago. More info.


Add to Portfolio Compare Print
24H Share Price and Events
7 Day Returns
11.4%
DB:24H
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-66.6%
DB:24H
-13.2%
DE Biotechs
-20.9%
DE Market
24H Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Hansa Biopharma (24H) 11.4% -14% -1.1% -66.6% - -
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • 24H underperformed the Biotechs industry which returned -13.2% over the past year.
  • 24H underperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
24H
Industry
5yr Volatility vs Market

Value

 Is Hansa Biopharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Hansa Biopharma to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Hansa Biopharma.

DB:24H Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.7%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:24H
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.19
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.188 (1 + (1- 22%) (0.29%))
1.128
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.13
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.128 * 5.44%)
5.74%

Discounted Cash Flow Calculation for DB:24H using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Hansa Biopharma is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:24H DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (SEK, Millions) Source Present Value
Discounted (@ 5.74%)
2020 -544.60 Analyst x4 -515.01
2021 -533.80 Analyst x4 -477.38
2022 -358.85 Analyst x2 -303.49
2023 70.00 Analyst x1 55.98
2024 433.00 Analyst x1 327.49
2025 721.67 Est @ 66.67% 516.17
2026 1,057.62 Est @ 46.55% 715.36
2027 1,401.01 Est @ 32.47% 896.14
2028 1,717.80 Est @ 22.61% 1,039.08
2029 1,987.67 Est @ 15.71% 1,137.01
Present value of next 10 years cash flows SEK3,391.00
DB:24H DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= SEK1,987.67 × (1 + -0.39%) ÷ (5.74% – -0.39%)
SEK32,274.94
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= SEK32,274.94 ÷ (1 + 5.74%)10
SEK18,462.29
DB:24H Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= SEK3,391.00 + SEK18,462.29
SEK21,853.29
Equity Value per Share
(SEK)
= Total value / Shares Outstanding
= SEK21,853.29 / 40.03
SEK545.98
DB:24H Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:24H represents 0.08034x of OM:HNSA
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.08034x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (SEK) x Listing Adjustment Factor
= SEK 545.98 x 0.08034
€43.86
Value per share (EUR) From above. €43.86
Current discount Discount to share price of €7.11
= -1 x (€7.11 - €43.86) / €43.86
83.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Hansa Biopharma is available for.
Intrinsic value
>50%
Share price is €7.11 vs Future cash flow value of €43.86
Current Discount Checks
For Hansa Biopharma to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Hansa Biopharma's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Hansa Biopharma's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Hansa Biopharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Hansa Biopharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:24H PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in SEK SEK-9.00
OM:HNSA Share Price ** OM (2020-04-03) in SEK SEK88.5
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Hansa Biopharma.

DB:24H PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:HNSA Share Price ÷ EPS (both in SEK)

= 88.5 ÷ -9.00

-9.84x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Hansa Biopharma is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Hansa Biopharma is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Hansa Biopharma's expected growth come at a high price?
Raw Data
DB:24H PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -9.84x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
34.2%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Hansa Biopharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Hansa Biopharma's assets?
Raw Data
DB:24H PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in SEK SEK14.06
OM:HNSA Share Price * OM (2020-04-03) in SEK SEK88.5
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:24H PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:HNSA Share Price ÷ Book Value per Share (both in SEK)

= 88.5 ÷ 14.06

6.29x

* Primary Listing of Hansa Biopharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Hansa Biopharma is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Hansa Biopharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Hansa Biopharma has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Hansa Biopharma expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
34.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Hansa Biopharma expected to grow at an attractive rate?
  • Hansa Biopharma's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Hansa Biopharma's earnings growth is expected to exceed the Germany market average.
  • Hansa Biopharma's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:24H Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:24H Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 34.2%
DB:24H Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 50.3%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:24H Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:24H Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 1,910 438 346 1
2023-12-31 1,082 75 98 2
2022-12-31 706 -356 -299 3
2021-12-31 140 -508 -517 4
2020-12-31 13 -517 -540 4
2020-04-06
DB:24H Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2019-12-31 3 -335 -360
2019-09-30 4 -317 -330
2019-06-30 3 -291 -298
2019-03-31 4 -262 -274
2018-12-31 3 -205 -248
2018-09-30 3 -176 -216
2018-06-30 3 -161 -192
2018-03-31 3 -150 -178
2017-12-31 3 -150 -177
2017-09-30 3 -148 -161
2017-06-30 3 -137 -151
2017-03-31 3 -121 -136

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Hansa Biopharma's earnings are expected to grow significantly at over 20% yearly.
  • Hansa Biopharma's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:24H Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Hansa Biopharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:24H Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 6.46 6.46 6.46 1.00
2023-12-31 0.04 0.04 0.04 1.00
2022-12-31 -6.80 -4.50 -8.14 3.00
2021-12-31 -12.09 -7.81 -15.67 4.00
2020-12-31 -12.96 -10.30 -16.90 4.00
2020-04-06
DB:24H Past Financials Data
Date (Data in SEK Millions) EPS *
2019-12-31 -9.00
2019-09-30 -8.30
2019-06-30 -7.56
2019-03-31 -7.05
2018-12-31 -6.47
2018-09-30 -5.73
2018-06-30 -5.19
2018-03-31 -4.91
2017-12-31 -4.96
2017-09-30 -4.59
2017-06-30 -4.38
2017-03-31 -4.04

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Hansa Biopharma will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Hansa Biopharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Hansa Biopharma has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Hansa Biopharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Hansa Biopharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Hansa Biopharma does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Hansa Biopharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Hansa Biopharma's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Hansa Biopharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Hansa Biopharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:24H Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 3.36 -360.01 167.31 192.95
2019-09-30 3.55 -330.38 150.17 177.93
2019-06-30 3.38 -297.57 128.03 167.19
2019-03-31 3.69 -273.96 104.37 165.60
2018-12-31 3.36 -247.97 90.39 154.56
2018-09-30 2.99 -215.73 67.72 147.69
2018-06-30 3.18 -191.81 53.54 142.49
2018-03-31 2.97 -178.16 49.38 132.37
2017-12-31 3.44 -176.66 43.72 137.06
2017-09-30 2.97 -161.23 38.53 126.31
2017-06-30 3.20 -150.63 36.89 114.55
2017-03-31 3.05 -136.15 34.54 103.67
2016-12-31 2.58 -111.13 29.70 82.85
2016-09-30 3.81 -96.68 25.61 73.19
2016-06-30 3.43 -83.68 23.65 62.32
2016-03-31 3.42 -75.52 26.87 50.86
2015-12-31 6.68 -66.27 28.24 44.26
2015-09-30 5.06 -59.93 25.91 36.23
2015-06-30 4.53 -51.43 22.25 31.58
2015-03-31 3.85 -33.77 6.64 30.55
2014-12-31 1.62 -29.04 7.61 21.74
2014-09-30 2.02 -20.73 12.90 14.17
2014-06-30 2.58 -19.77 17.84 9.98
2014-03-31 3.06 -19.24 24.05 -0.25
2013-12-31 1.79 -17.56 18.89
2013-09-30 2.16 -16.47 20.07 0.00
2013-06-30 2.53 -15.37 21.39 0.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Hansa Biopharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Hansa Biopharma has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Hansa Biopharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Hansa Biopharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Hansa Biopharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Hansa Biopharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Hansa Biopharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Hansa Biopharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Hansa Biopharma's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Hansa Biopharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 843.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Hansa Biopharma Company Filings, last reported 3 months ago.

DB:24H Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 562.82 0.73 601.09
2019-09-30 668.12 0.78 680.16
2019-06-30 755.40 0.74 762.73
2019-03-31 835.07 0.74 759.23
2018-12-31 859.88 0.00 858.19
2018-09-30 506.30 0.00 483.40
2018-06-30 542.97 0.00 534.18
2018-03-31 591.81 0.00 575.05
2017-12-31 630.66 0.40 616.06
2017-09-30 167.89 0.57 130.87
2017-06-30 198.60 0.00 169.95
2017-03-31 240.07 0.56 209.35
2016-12-31 283.69 0.00 253.58
2016-09-30 138.81 0.00 103.95
2016-06-30 160.20 0.00 133.69
2016-03-31 190.92 0.00 158.08
2015-12-31 211.53 0.00 175.68
2015-09-30 230.06 0.00 192.63
2015-06-30 244.07 0.00 209.11
2015-03-31 39.51 0.00 7.08
2014-12-31 49.80 0.00 10.15
2014-09-30
2014-06-30 70.75 0.00 25.22
2014-03-31 45.35 0.69 0.09
2013-12-31 45.35 0.52 0.09
2013-09-30 45.35 0.52 0.09
2013-06-30 54.60 0.00 9.14
  • Hansa Biopharma's level of debt (0.1%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 0.1% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Hansa Biopharma has sufficient cash runway for 1.8 years based on current free cash flow.
  • Hansa Biopharma has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 41.9% each year.
X
Financial health checks
We assess Hansa Biopharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Hansa Biopharma has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Hansa Biopharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Hansa Biopharma dividends. Estimated to be 0% next year.
If you bought €2,000 of Hansa Biopharma shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Hansa Biopharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Hansa Biopharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:24H Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:24H Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.00 1.00
2021-12-31 0.00 2.00
2020-12-31 0.00 2.00
2020-04-06

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Hansa Biopharma has not reported any payouts.
  • Unable to verify if Hansa Biopharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Hansa Biopharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Hansa Biopharma has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Hansa Biopharma's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Hansa Biopharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Hansa Biopharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Hansa Biopharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Hansa Biopharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Søren Tulstrup
AGE 54
TENURE AS CEO 2.1 years
CEO Bio

Mr. Søren Tulstrup, M.Sc, has been Chief Executive Officer of Hansa Medical AB (publ) since March 20, 2018 and served as its President since March 20, 2018 until 2020. Mr. Tulstrup served as the Chief Executive Officer of Vifor Pharma Ltd. since August 12, 2014 until May 24, 2016. Mr. Tulstrup joined the Galenica Group in 2014. He served as a Senior Vice President and Franchise Lead of Mucopolysaccharides for Shire Human Genetic Therapies, Inc. at Shire plc since July 31, 2012. He was responsible for developing global strategy for MPS franchise, which includes both commercial and pipeline products and plays a key role in strategic decisions made about Shire Human Genetic Therapies, Inc. growing rare disease portfolio. He has almost two decades of international experience within the Pharmaceutical Industry. He served as Head Global Franchise (MPS) at Shire Pharmaceuticals, Switzerland/USA. He served as the Chief Executive Officer and President of Santaris Pharma A/S from June 2008 to 2012, where he led business development efforts resulting in four major partnership agreements, including an ongoing collaboration with Shire. He served as Vice President of Global Human Health at Merck & Co., Inc. in New Jersey, USA. From 2003 to 2006, he served as the first Managing Director of Merck, Sharp & Dohme Ireland Ltd. (Human Health), which he built into a well-established subsidiary and one of the leading pharmaceutical companies in Ireland. He joined Merck, Sharp & Dohme Denmark, and a subsidiary of Merck & Co., Inc. in 1996 and served as its Managing Director of Operations since 1999 until 2003. While at Merck & Co, he spearheaded the global roll-out of a key diabetes product from Phase III to launch and he was part of a team that led integration of its US based Human Health commercial operations into the Global Human Health organization. He has also held sales and marketing positions at Abbott Laboratories from 1990 to 1992. He worked at Sandoz Pharma Ltd. from 1992 to 1996. He held various general management positions at Merck & Co., Inc., Denmark, Ireland and USA from 1996 to 2008. From 1996 to 1999, he served as Sales & Marketing Director of MSD Denmark. He established MSD Ireland (Human Health), another fully owned subsidiary of Merck in 2003 and served as its First Managing Director until 2006. He served as First Country Manager of Hungary, Romania and Baltic States and Deputy Regional Manager of Europe at Sandoz (now Novartis) in Basel, Switzerland. He served as an Officer of an armored infantry regiment. He serves as Vice Chairman of European Biopharmaceutical Enterprises. He served as a Board Director of miRagen Therapeutics. He is a graduate of the Danish Army Military Academy. He holds a Bachelor of Business Administration in International Business and Modern Languages from Copenhagen Business School. He holds a Master of Science in Economics and Business Administration at the Copenhagen Business School and JL Kellogg Graduate School of management, Northwestern University, Chicago.

CEO Compensation
  • Insufficient data for Søren to compare compensation growth.
  • Insufficient data for Søren to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Hansa Biopharma management team in years:

0.9
Average Tenure
51
Average Age
  • The average tenure for the Hansa Biopharma management team is less than 2 years, this suggests a new team.
Management Team

Søren Tulstrup

TITLE
Chief Executive Officer
AGE
54
TENURE
2.1 yrs

Donato Spota

TITLE
CFO & Senior VP
AGE
48
TENURE
0.9 yrs

Christian Kjellman

TITLE
Senior VP
AGE
52
TENURE
0.2 yrs

Eva-Maria Joed

TITLE
Vice President of Finance & Administration
AGE
50
TENURE
0.9 yrs

Klaus Sindahl

TITLE
Head of Investor Relations

Anne Lanner

TITLE
Vice President of Global Human Resources
AGE
50
TENURE
1.3 yrs

Henk J. van Troostwijk

TITLE
Senior VP & Chief Commercial Officer
AGE
54
TENURE
0.8 yrs
Board of Directors Tenure

Average tenure and age of the Hansa Biopharma board of directors in years:

1.9
Average Tenure
64.5
Average Age
  • The average tenure for the Hansa Biopharma board of directors is less than 3 years, this suggests a new board.
Board of Directors

Ulf Wiinberg

TITLE
Chairman of the Board
COMPENSATION
SEK3M
AGE
61
TENURE
2.1 yrs

Birgit Norinder

TITLE
Director
COMPENSATION
SEK467K
AGE
71
TENURE
8.3 yrs

Gunnar Tufveson

TITLE
Chairman of European Medical Advisory Board in Transplantation

Stanley Jordan

TITLE
Chairman of US Medical Advisory Board in Transplantation

Eva Nilsagård

TITLE
Director
AGE
55
TENURE
0.9 yrs

Kathryn Wood

TITLE
Member - European Medical Advisory Board-Transplantation & US Medical Advisory Board-Transplantation

Christophe Legendre

TITLE
Member of European Medical Advisory Board in Transplantation

Robert Montgomery

TITLE
Member of US Medical Advisory Board in Transplantation

Anders Pedersen

TITLE
Director
COMPENSATION
SEK210K
AGE
68
TENURE
1.9 yrs

Andreas Eggert

TITLE
Director
COMPENSATION
SEK204K
TENURE
1.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
21. Dec 19 Buy Max Sakajja Individual 19. Dec 19 20. Dec 19 2,000 €7.50 €14,812
20. Dec 19 Buy Vincenza Nigro Individual 17. Dec 19 17. Dec 19 3,000 €6.67 €20,004
20. Dec 19 Buy Anders Pedersen Individual 18. Dec 19 18. Dec 19 2,500 €6.93 €17,333
18. Dec 19 Buy Birgit Norinder Individual 17. Dec 19 17. Dec 19 3,000 €6.79 €20,363
18. Dec 19 Buy Ulf Wiinberg Individual 17. Dec 19 17. Dec 19 14,350 €6.78 €97,320
17. Dec 19 Buy Søren Tulstrup Individual 16. Dec 19 16. Dec 19 5,000 €6.86 €34,276
16. Dec 19 Buy Andreas Eggert Individual 16. Dec 19 16. Dec 19 3,000 €6.43 €19,275
13. Dec 19 Buy Eva-Maria Joed Individual 13. Dec 19 13. Dec 19 1,000 €6.99 €6,994
05. Nov 19 Buy Ulf Wiinberg Individual 04. Nov 19 04. Nov 19 15,000 €11.54 €173,128
04. Jun 19 Buy Max Sakajja Individual 04. Jun 19 04. Jun 19 1,900 €15.51 €29,465
24. May 19 Buy Andreas Eggert Individual 24. May 19 24. May 19 2,500 €16.74 €41,850
23. May 19 Buy Anne Lanner Individual 11. Feb 19 29. Apr 19 360 €20.86 €7,246
22. May 19 Buy Ulf Wiinberg Individual 21. May 19 21. May 19 10,000 €16.18 €161,759
05. May 19 Buy Søren Tulstrup Individual 03. May 19 03. May 19 5,000 €17.32 €86,597
03. May 19 Sell Emanuel Björne Individual 02. May 19 02. May 19 -20,000 €16.84 €-336,761
X
Management checks
We assess Hansa Biopharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Hansa Biopharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Hansa Biopharma AB (publ), a biopharmaceutical company, focuses on developing novel immunomodulatory enzymes for organ transplantation and autoimmune diseases. The company’s lead drug candidate is Immunoglobulin G-degrading enzyme of Streptococcus pyogenes (IdeS), a proprietary antibody-degrading enzyme for kidney transplant patients, as well as for antibody disease and guillain barre syndrome. Its preclinical stage product candidates include Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), a cancer immunotherapy. The company also has collaborative agreement with Axis-Shield Diagnostics Limited to develop Heparin Binding Protein (HBP)-assay, a novel diagnostic method that predicts severe sepsis in patients with infectious disease symptoms. Hansa Biopharma AB (publ) was founded in 2001 and is headquartered in Lund, Sweden.

Details
Name: Hansa Biopharma AB (publ)
24H
Exchange: DB
Founded: 2001
SEK322,570,804
40,026,107
Website: http://www.hansabiopharma.com
Address: Hansa Biopharma AB (publ)
Scheelevägen 22,
Lund,
Skåne County, 222 63,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM HNSA Class B Shares OMX Nordic Exchange Stockholm SE SEK 17. Oct 2007
OTCPK HNSB.F Class B Shares Pink Sheets LLC US USD 17. Oct 2007
DB 24H Class B Shares Deutsche Boerse AG DE EUR 17. Oct 2007
LSE 0RC7 Class B Shares London Stock Exchange GB SEK 17. Oct 2007
BMV HNSA N Class B Shares Bolsa Mexicana de Valores MX MXN 17. Oct 2007
Number of employees
Current staff
Staff numbers
74
Hansa Biopharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 00:56
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/20
Last earnings filing: 2020/02/06
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.